How quickly does Masten-100 Drostanolone Propionate start working after the first injection?

Masten-100 begins establishing meaningful plasma drostanolone concentrations within 24–48 hours of the initial injection, due to the propionate ester's rapid hydrolysis rate. Most users notice early androgenic effects — increased muscular hardness, reduced water retention — within 4–7 days of starting a consistent dosing protocol of every other day (EOD) injections.

Why does the propionate ester cause Drostanolone to kick in faster than other ester variants?

The propionate ester consists of a short three-carbon chain that esterase enzymes cleave more rapidly than longer chains such as enanthate or decanoate. This faster hydrolysis releases free drostanolone into circulation sooner, shortening the lag between injection and peak plasma concentration. Pharmacokinetically, propionate reaches its peak roughly 24–48 hours post-injection versus 3–5 days for the enanthate ester.

What are the reliable signs that Masten-100 is actually producing the expected androgenic effect?

Objective indicators include measurable reductions in subcutaneous water retention tracked by caliper skinfold assessment, stable or increasing lean bodyweight without concurrent scale-weight gain from water, and enhanced muscular density visually and to palpation. Serum androgen levels confirmed via LCMS/MS blood analysis provide the most quantitative verification that circulating drostanolone concentrations are within an active range.

What is the advantage of the single-dose 1ml ampoule format compared to multi-use vials for an EOD protocol?

Single-dose ampoules eliminate repeated needle-entry contamination risk inherent in multi-use vials, and each ampoule delivers a precise, pre-measured 100mg dose with no partial-draw calculation required. For an every-other-day protocol — the standard Drostanolone Propionate schedule — this means every injection uses a sterile, sealed unit, significantly reducing bacteriostatic preservative dependency and cross-contamination exposure across a full cycle.

Is 100mg/ml the right concentration for someone new to Drostanolone Propionate, and how does it differ from higher concentrations?

Yes — 100mg/ml is the most practical starting concentration for Drostanolone Propionate because it allows flexible dosing without the injection-site discomfort sometimes associated with higher-concentration formulations (150mg/ml+). A standard 1ml injection delivers exactly 100mg, making dose increments straightforward. Higher concentrations reduce injection volume but can increase local tissue irritation, especially for propionate-ester compounds known for greater injection-site sensitivity. (2) angle_used

Fast Acting

BM Pharmaceuticals

Masten-100 100mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Name: Masten-100 100mg/ml 10x1ml Ampoules by BM Pharmaceuticals
Brand: BM Pharmaceuticals
SKU: INJ-DROP-BM-100-002
Price: 47.00 EUR
Availability: InStock

Masten-100 is a fast-acting injectable androgenic compound delivering Drostanolone Propionate at 100mg/ml in single-dose 1ml ampoules, specifically engineered for rapid tissue uptake and measurable efficacy within the first days of administration. The propionate ester's short carbon chain enables peak plasma concentrations to establish quickly — typically within 24–48 hours of the first injection — making it one of the fastest-onset drostanolone formulations available. Every lot is released only after HPLC potency confirmation and LAL endotoxin screening; sterility is assured via Ph. Eur. 2.6.1-compliant testing conducted at BM Pharmaceuticals' GMP-certified facility.

€47.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Rapid plasma-level establishment within 24–48 hours enables early cycle feedback and quick dosing adjustments.
Anti-aromatase activity at the receptor level delivers a dry, dense muscular appearance without concurrent estrogen management compounds in many protocols.
100mg/ml concentration supports precise incremental dosing suitable for both introductory and maintenance phases.
Single-dose sealed ampoule format maintains sterility integrity at every injection event throughout the cycle.
Short propionate half-life of approximately 2–3 days allows rapid clearance — practical for tested athletes managing detection windows.
GMP-manufactured with HPLC and LAL batch release testing ensures the stated 100mg/ml potency is verifiably delivered.
2α-methyl modification confers inherent aromatase resistance, reducing the estrogenic interference that can slow onset of visible physique changes.

Phase	Dosage	Note
Onset / Loading Week (Week 1–2)	100mg every other day (EOD)	Propionate ester reaches peak plasma levels at ~24–48 h; EOD scheduling front-loads stable concentration, accelerating the onset of androgenic efficacy.
Active Maintenance (Week 3–8)	100–150mg EOD (1–1.5ml)	Consistent EOD injection cadence maintains trough concentrations above the androgenic threshold; monitor density and water-retention response weekly to confirm compound efficacy.
Pre-Contest / Taper (Final 2 Weeks)	100mg EOD	Returning to 100mg EOD preserves lean tissue while allowing rapid clearance before event date; short half-life means blood levels decline within 4–6 days of last injection.
PCT Initiation	Begin PCT 3–4 days after last injection	Short ester clearance window means PCT (e.g. Clomiphene or Tamoxifen) can begin sooner than with long-ester androgens, minimising suppression duration.

Key takeaways

Expect measurable onset within 24–48 hours of your first injection.
Choose EOD injection timing to maintain stable plasma drostanolone levels.
Monitor skinfold thickness weekly to confirm the compound is actively working.
Use single-dose ampoules to eliminate partial-draw and contamination errors.
Verify batch potency via HPLC Certificate of Analysis before use.

Drostanolone Propionate as a Fast-Onset Androgenic Agent

Masten-100 delivers Drostanolone Propionate — a 2α-methyl-dihydrotestosterone derivative — at a concentration of 100mg/ml, formulated specifically to maximise the speed of systemic availability through the propionate ester's abbreviated side-chain hydrolysis pathway. Compared to longer-ester drostanolone formulations such as the enanthate variant, Drostanolone Propionate reaches meaningful circulating concentrations significantly faster, with pharmacokinetic data indicating peak plasma levels within 24–48 hours post-injection rather than the 3–5 day lag associated with enanthate. This rapid onset is the defining clinical characteristic that drives protocol selection when athletes need a compound that responds quickly to dosing adjustments.

Mechanism Behind the Rapid Kick-In

Drostanolone Propionate exerts its primary effects through direct androgen receptor (AR) binding, where the 2α-methyl modification confers resistance to aromatase-mediated conversion — meaning estrogenic side effects do not blunt or delay the compound's androgenic efficacy signal. The propionate ester undergoes esterase-catalysed hydrolysis within muscle tissue and systemic circulation, releasing free drostanolone rapidly. Masten-100 binds androgen receptors in skeletal muscle and exerts anti-estrogenic properties by competing with circulating estrogen at the receptor level. This dual mechanism — direct AR agonism plus peripheral anti-estrogenic activity — means users typically report onset of observable effects, including increased muscular density and reduced subcutaneous water retention, within the first week of a correctly timed protocol.

Concentration, Ampoule Format, and Dosing Precision

At 100mg/ml, Masten-100 is positioned at the entry-concentration level within drostanolone propionate products — a deliberate formulation choice that enables precise, incremental dosing without the volume constraints associated with higher-concentration preparations. Each 1ml single-dose ampoule delivers exactly 100mg of active compound per injection event, eliminating the partial-draw errors and contamination risks inherent in multi-use vial formats. BM Pharmaceuticals manufactures Masten-100 under WHO-aligned GMP conditions; HPLC chromatographic analysis confirms potency at each batch release, and LAL (Limulus Amebocyte Lysate) endotoxin testing verifies pyrogen-free status prior to distribution.

Efficacy Indicators and Monitoring

Because onset is rapid, objective efficacy monitoring can begin early in a Masten-100 cycle. Bodyweight stability alongside measurable reductions in skinfold thickness — tracked via caliper assessment at consistent anatomical sites — serves as an early, quantifiable indicator that the compound is eliciting the expected anti-estrogenic and androgenic response. Serum androgen levels, measurable via LCMS/MS methodology, confirm that drostanolone concentrations are within the therapeutically relevant range for the protocol employed.

Usage

Confirm the lot number on the ampoule matches your Certificate of Analysis (CoA) — verify HPLC potency data before drawing the dose.
Snap the ampoule neck cleanly using the scored break-point; inspect the solution for clarity and absence of particulate matter before drawing.
Draw 1ml using an 18–21G drawing needle into a sterile syringe, then switch to a fresh 23–25G injection needle to minimise tissue trauma at the injection site.
Administer via intramuscular injection (glute, vastus lateralis, or deltoïd) rotating sites across each EOD injection to reduce local accumulation and propionate-related injection-site irritation.
Inject at room temperature — if ampoules were stored refrigerated, allow the solution to reach ~20–22°C before administration to reduce viscosity and injection discomfort.
Log injection time and site with each administration; because onset is rapid with propionate, begin tracking physique markers (bodyweight, skinfold, muscular hardness) from Day 5 onward to establish an early efficacy baseline.

Warnings

Contraindications: Masten-100 is contraindicated in individuals with diagnosed prostate carcinoma, breast carcinoma (males), severe hepatic impairment, or known hypersensitivity to drostanolone or any sesame/benzyl-based excipient. Women of childbearing potential should not use this product due to virilisation risk; androgenic compounds carry teratogenic potential in early pregnancy.

Side Effects: Androgenic side effects include accelerated androgenetic alopecia in genetically predisposed individuals, acne vulgaris, and increased sebum production. Despite drostanolone's intrinsic aromatase resistance, supraphysiological androgen exposure can suppress natural LH and FSH secretion, resulting in testicular atrophy and reduced endogenous testosterone output during the cycle. Elevated haematocrit (polycythaemia) is a dose-dependent risk requiring periodic monitoring.

Monitoring: Baseline and on-cycle blood panels should include: serum testosterone (total and free), LH, FSH, haematocrit/haemoglobin, lipid profile (HDL suppression is a documented androgenic effect), and hepatic enzyme markers (ALT/AST). Frequency recommendation: baseline before cycle, mid-cycle at week 4–5, and post-cycle before PCT initiation.

PCT: Post-cycle therapy is mandatory following any suppressive androgen cycle. Given Masten-100's short propionate half-life (~2–3 days), PCT with a SERM (Selective Estrogen Receptor Modulator — e.g. Tamoxifen 20mg/day or Clomiphene 50mg/day) can commence 3–4 days after the final injection. Standard PCT duration: 4 weeks minimum, with blood-work confirmation of endogenous testosterone recovery before discontinuation.

Frequently asked questions

How quickly does Masten-100 Drostanolone Propionate start working after the first injection?: Masten-100 begins establishing meaningful plasma drostanolone concentrations within 24–48 hours of the initial injection, due to the propionate ester's rapid hydrolysis rate. Most users notice early androgenic effects — increased muscular hardness, reduced water retention — within 4–7 days of starting a consistent dosing protocol of every other day (EOD) injections.
Why does the propionate ester cause Drostanolone to kick in faster than other ester variants?: The propionate ester consists of a short three-carbon chain that esterase enzymes cleave more rapidly than longer chains such as enanthate or decanoate. This faster hydrolysis releases free drostanolone into circulation sooner, shortening the lag between injection and peak plasma concentration. Pharmacokinetically, propionate reaches its peak roughly 24–48 hours post-injection versus 3–5 days for the enanthate ester.
What are the reliable signs that Masten-100 is actually producing the expected androgenic effect?: Objective indicators include measurable reductions in subcutaneous water retention tracked by caliper skinfold assessment, stable or increasing lean bodyweight without concurrent scale-weight gain from water, and enhanced muscular density visually and to palpation. Serum androgen levels confirmed via LCMS/MS blood analysis provide the most quantitative verification that circulating drostanolone concentrations are within an active range.
What is the advantage of the single-dose 1ml ampoule format compared to multi-use vials for an EOD protocol?: Single-dose ampoules eliminate repeated needle-entry contamination risk inherent in multi-use vials, and each ampoule delivers a precise, pre-measured 100mg dose with no partial-draw calculation required. For an every-other-day protocol — the standard Drostanolone Propionate schedule — this means every injection uses a sterile, sealed unit, significantly reducing bacteriostatic preservative dependency and cross-contamination exposure across a full cycle.
Is 100mg/ml the right concentration for someone new to Drostanolone Propionate, and how does it differ from higher concentrations?: Yes — 100mg/ml is the most practical starting concentration for Drostanolone Propionate because it allows flexible dosing without the injection-site discomfort sometimes associated with higher-concentration formulations (150mg/ml+). A standard 1ml injection delivers exactly 100mg, making dose increments straightforward. Higher concentrations reduce injection volume but can increase local tissue irritation, especially for propionate-ester compounds known for greater injection-site sensitivity. (2) angle_used

Manufacturer

BM Pharmaceuticals' product portfolio spans a deliberately curated range of injectable anabolic compounds — each formulation representing a specific market need rather than blanket catalogue expansion. Masten-100 sits within the company's dedicated short-ester product line: a subset of the portfolio engineered for rapid-onset applications, where consistent concentration and ester fidelity are non-negotiable for protocol reliability. The 100mg/ml Drostanolone Propionate ampoule is one of several single-ingredient, single-dose formats in this line — a format philosophy that reflects BM Pharmaceuticals' institutional stance that injectable compounds should enter each administration event from a sealed, sterile container with no residual contamination risk from prior use. Across the full injectable portfolio, release specifications are uniform in their analytical rigour: HPLC-verified potency, LAL endotoxin screening, and sterility testing aligned with Ph. Eur. 2.6.1. What differentiates the short-ester line commercially is the precision expectation it carries — athletes selecting propionate formulations need concentration accuracy more urgently than those on long-ester protocols, because dosing errors surface in blood levels within 24–48 hours rather than days later. BM Pharmaceuticals' QC infrastructure is structured to meet exactly that expectation.

Product details

Brand	BM Pharmaceuticals
Active ingredient	drostanolone propionate
Also known as	Masteron, Drolban, Drostanolone Propionate, Masten-100, BM Pharmaceuticals Masteron
Strength	100 mg
Form	Ampullen
Pack size	10 pieces
Item number	INJ-DROP-BM-100-002

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Optimal Dosage

Propha-Masteron 100mg/ml 10ml Vial by Beligas Pharmaceuticals

Propha-Masteron is an oil-based injectable solution delivering Drostanolone Propionate at 100mg/ml, distinguished by its capacity to bypass hepatic first-pass metabolism entirely — a pharmacokinetic advantage that oral androgen compounds cannot replicate. Each 10ml multi-dose vial provides a full cycle's supply of pharmaceutical-grade active, with systemic absorption occurring directly through intramuscular tissue into the bloodstream. Quality assurance is built into every lot: HPLC potency verification, LAL endotoxin screening, and GMP-certified filling suites are standard — not optional — at Beligas Pharmaceuticals.

€46.00

High Concentration

MasterTrex 150mg/ml 10ml Vial by Concentrex Labs

MasterTrex is a high-concentration Drostanolone Propionate injectable, formulated at 150 mg/ml in a 10 ml multi-dose vial and engineered for athletes who demand precise, schedule-driven injection timing across their cutting or pre-contest phase. At 150 mg/ml, each draw delivers a clinically meaningful dose in a compact volume, making every-other-day or every-third-day scheduling straightforward without excess injection site load. Quality is locked in at batch level: HPLC-quantified potency verification and LAL endotoxin testing are completed before any MasterTrex vial leaves the Concentrex Labs facility.

€50.00

Brand Quality

Masteron 100 100mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma Masteron 100 is a drostanolone propionate injectable solution at 100mg/ml in a 10ml multi-dose vial, specifically suited to frontloading protocols that compress the time-to-steady-state window at the opening of a cycle. Because the propionate ester releases active drostanolone within a short half-life of approximately 2–3 days, calculated loading doses can bring circulating androgen levels to the target therapeutic range within the first 72 hours rather than waiting the usual week or more. Dragon-Pharma batch-releases every vial only after HPLC potency verification and LAL endotoxin clearance — two independent quality gates applied sequentially before product leaves the facility.

€42.00

Pro Choice

Mastelad 100mg/ml 10ml Vial by Driada Medical

Mastelad by Driada Medical is a pharmaceutical-grade injectable androgenic compound delivering Drostanolone Propionate at 100 mg/ml in a 10 ml multi-dose vial, purpose-built for cutting and body-definition cycles where preserving lean muscle during a caloric deficit is the primary objective. Its short-ester structure enables precise cycle management, making mid-cycle dosage adjustments straightforward without prolonged systemic carry-over. Quality is assured through the following controls: each 10 ml batch is subject to reversed-phase HPLC potency verification and a Bacterial Endotoxin Test (LAL method) prior to release.

€50.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00